
## Michal Sarfaty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6990489/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immune-Related Thyroiditis as a Predictor for Survival in Metastatic Renal Cell Carcinoma. Cancers, 2022, 14, 875.	1.7	3
2	Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314 Journal of Clinical Oncology, 2022, 40, 4522-4522.	0.8	3
3	RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. Cancers, 2022, 14, 3127.	1.7	5
4	Central nervous system metastases in breast cancer: the impact of age on patterns of development and outcome. Breast Cancer Research and Treatment, 2021, 185, 423-432.	1.1	5
5	Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Breast Cancer Research and Treatment, 2021, 188, 379-387.	1.1	3
6	Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. Clinical Genitourinary Cancer, 2021, 19, e178-e183.	0.9	2
7	Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast, 2021, 60, 62-69.	0.9	88
8	A phase II trial of durvalumab and tremelimumab in metastatic, nonâ€urothelial carcinoma of the urinary tract. Cancer Medicine, 2021, 10, 1074-1083.	1.3	10
9	The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis. Cancers, 2021, 13, 5977.	1.7	1
10	Nextâ€generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience. Head and Neck, 2020, 42, 599-607.	0.9	8
11	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in realâ€world earlyâ€stage breast cancer. Cancer Medicine, 2020, 9, 4603-4612.	1.3	3
12	Antibody-Drug Conjugates in Urothelial Carcinomas. Current Oncology Reports, 2020, 22, 13.	1.8	21
13	MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy Journal of Clinical Oncology, 2020, 38, e17034-e17034.	0.8	0
14	Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis. JNCI Cancer Spectrum, 2019, 3, pkz033.	1.4	20
15	The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States. Clinical Colorectal Cancer, 2019, 18, 209-217.	1.0	6
16	A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma. Oncologist, 2019, 24, 366-371.	1.9	26
17	The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States. Journal of Oncology, 2019, 2019, 1-8.	0.6	22
18	Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer. European Urology, 2018, 74, 57-62.	0.9	56

MICHAL SARFATY

#	Article	IF	CITATIONS
19	Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma. European Urology, 2018, 73, 628-634.	0.9	57
20	Early PET T in patients with pathological stage III colon cancer may improve their outcome: Results from a large retrospective study. Cancer Medicine, 2018, 7, 5470-5477.	1.3	3
21	RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. Clinical Lung Cancer, 2017, 18, e223-e232.	1.1	24
22	Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab. Medicine (United States), 2017, 96, e5951.	0.4	15
23	Esophageal Cancer in Israel has Unique Clinico-Pathological Features: A Retrospective Study. Journal of Cancer, 2017, 8, 2417-2423.	1.2	3
24	Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma. Radiation Oncology, 2017, 12, 163.	1.2	55
25	Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. Journal of Cancer, 2016, 7, 883-889.	1.2	4
26	Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World. Oncologist, 2016, 21, 907-909.	1.9	13
27	A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer. PLoS ONE, 2016, 11, e0157548.	1.1	5
28	Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy. BioMed Research International, 2015, 2015, 1-7.	0.9	11
29	Esophageal cancer in Israel: A unique clinicopathological entity?. Journal of Clinical Oncology, 2015, 33, e15050-e15050.	0.8	0
30	Are all RET fusions NSCLC alike? Clinical pitfalls and response to targeted therapy: KIF5B vs. CCDC6 Journal of Clinical Oncology, 2015, 33, e19005-e19005.	0.8	0
31	New paradigm for the treatment of metastatic salivary gland tumors Journal of Clinical Oncology, 2014, 32, e17043-e17043.	0.8	0
32	Outcome of percutaneous endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis in relation to respiratory dysfunction. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 528-532.	1.1	27